company background image
BYSI

BeyondSpring NasdaqCM:BYSI Stock Report

Last Price

US$1.39

Market Cap

US$54.1m

7D

0%

1Y

-87.0%

Updated

25 Jun, 2022

Data

Company Financials +
BYSI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BYSI Stock Overview

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.

BeyondSpring Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for BeyondSpring
Historical stock prices
Current Share PriceUS$1.39
52 Week HighUS$33.00
52 Week LowUS$1.13
Beta1.2
1 Month Change23.01%
3 Month Change-37.39%
1 Year Change-87.02%
3 Year Change-94.14%
5 Year Change-96.76%
Change since IPO-91.73%

Recent News & Updates

Shareholder Returns

BYSIUS BiotechsUS Market
7D0%10.3%6.6%
1Y-87.0%-24.4%-18.5%

Return vs Industry: BYSI underperformed the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: BYSI underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is BYSI's price volatile compared to industry and market?
BYSI volatility
BYSI Average Weekly Movement17.1%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: BYSI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: BYSI's weekly volatility has decreased from 30% to 17% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010103Lan Huanghttps://www.beyondspringpharma.com

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.

BeyondSpring Fundamentals Summary

How do BeyondSpring's earnings and revenue compare to its market cap?
BYSI fundamental statistics
Market CapUS$54.11m
Earnings (TTM)-US$64.18m
Revenue (TTM)US$1.35m

40.1x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BYSI income statement (TTM)
RevenueUS$1.35m
Cost of RevenueUS$0
Gross ProfitUS$1.35m
Other ExpensesUS$65.53m
Earnings-US$64.18m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.65
Gross Margin100.00%
Net Profit Margin-4,750.48%
Debt/Equity Ratio5.9%

How did BYSI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BYSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BYSI?

Other financial metrics that can be useful for relative valuation.

BYSI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does BYSI's PS Ratio compare to its peers?

BYSI PS Ratio vs Peers
The above table shows the PS ratio for BYSI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.4x

Price-To-Sales vs Peers: BYSI is expensive based on its Price-To-Sales Ratio (40.1x) compared to the peer average (19.4x).


Price to Earnings Ratio vs Industry

How does BYSI's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: BYSI is expensive based on its Price-To-Sales Ratio (40.1x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is BYSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BYSI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio40.1x
Fair PS Ratio129.6x

Price-To-Sales vs Fair Ratio: BYSI is good value based on its Price-To-Sales Ratio (40.1x) compared to the estimated Fair Price-To-Sales Ratio (129.6x).


Share Price vs Fair Value

What is the Fair Price of BYSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BYSI's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is BeyondSpring forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BYSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BYSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BYSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BYSI's revenue (52.2% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: BYSI's revenue (52.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BYSI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has BeyondSpring performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BYSI is currently unprofitable.

Growing Profit Margin: BYSI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BYSI is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BYSI has a negative Return on Equity (-258.59%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is BeyondSpring's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BYSI's short term assets ($75.1M) exceed its short term liabilities ($15.2M).

Long Term Liabilities: BYSI's short term assets ($75.1M) exceed its long term liabilities ($40.1M).


Debt to Equity History and Analysis

Debt Level: BYSI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BYSI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BYSI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BYSI has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 23.5% each year.


Discover healthy companies

Dividend

What is BeyondSpring current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BYSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BYSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BYSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BYSI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BYSI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Lan Huang (50 yo)

7.58yrs

Tenure

Dr. Lan Huang, Ph D., co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and serves as its Chairman and Chief Executive Officer. Dr. Huang Co-founded BeyondSpring Inc. and has been its Chairman and Chi...


Leadership Team

Experienced Management: BYSI's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: BYSI's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BeyondSpring Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BeyondSpring Inc.
  • Ticker: BYSI
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$54.109m
  • Shares outstanding: 38.93m
  • Website: https://www.beyondspringpharma.com

Number of Employees


Location

  • BeyondSpring Inc.
  • 28 Liberty Street
  • 39th Floor
  • New York
  • New York
  • 10005
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.